CopenFast trial: Faster-acting insulin Fiasp versus insulin NovoRapid in the treatment of women with type 1 or type 2 diabetes during pregnancy and lactation - a randomised controlled trial

INTRODUCTION: Faster-acting insulin aspart (Fiasp) is approved for use in pregnancy and lactation, but no clinical study has evaluated its effects during this life stage in women with pre-existing diabetes. The aim of the CopenFast trial is to evaluate the effect of Fiasp compared with insulin aspar...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:BMJ Open
Main Authors: Nørgaard, Sidse Kjærhus, Mathiesen, Elisabeth Reinhardt, Nørgaard, Kirsten, Clausen, Tine Dalsgaard, Damm, Peter, Ringholm, Lene
Formato: Artigo
Idioma:Inglês
Publicado: BMJ Publishing Group 2021
Assuntos:
Diabetes and Endocrinology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8043014/
https://ncbi.nlm.nih.gov/pubmed/33837106
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2020-045650
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares